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Abstract: After the introduction of antiretroviral therapy (ART) the life expectancy of patients infected
with human immunodeficiency virus (HIV) is now approaching that of the general population and
the importance of non-AIDS co-morbidities is increasing. Specifically, the risk of coronary artery
disease (CAD) seems to be higher in HIV-infected patients and an accurate risk prediction of CAD
is of high importance for optimal long term treatment. In this study, we assessed the correlation of
the endoPAT, which is an office-based CVD screening tool with the myocardial perfusion reserve
by 82-rubidium PET/CT. We measured the reactive hyperemia index, which is a measure of the
endothelial responsiveness, by the use of an endoPAT device (Itamar Medical, Caesarea, Israel) in
48 ART treated HIV-infected patients with high CD 4 cell counts and viral suppression (HIV-RNA <
20 copies/mL), who had previously undergone measurement of the myocardial perfusion reserve
by 82-rubidium PET/CT for study purposes. We found an inverse correlation between the reactive
hyperemia index and the myocardial perfusion reserve which most likely indicates different vascular
physiology. This study did not find evidence to suggest the immediate implementation of the reactive
hyperemia index as a screening tool for early coronary artery disease in well-treated HIV-infected
patients pending further validation in larger prospective studies.
Keywords: reactive hyperemia index; HIV; cardiovascular risk; myocardial perfusion reserve
1. Introduction
After the introduction of antiretroviral therapy (ART), the life expectancy of patients infected
with human immunodeficiency virus (HIV) is now approaching that of the general population [1,2]
and the importance of non-AIDS co-morbidities is increasing [3]. Specifically, the risk of coronary
artery disease (CAD) seems to be higher in HIV-infected patients [4–6]. The pathogenesis behind this
increased risk is not fully understood but seems to involve not only modifiable traditional risk factors,
such as hypertension and smoking, but also more subtle immunological changes related to the chronic
infection [7,8]. These factors seem to have potential influence on the vasculature of some HIV-infected
patients [9–11] and accurate, easy risk prediction of CAD is of high importance for optimal long
term treatment. Very early in the development towards fulminant, morphological cardiovascular
disease the endothelium becomes activated/dysfunctional and plays a pivotal role in the development
of atherosclerotic lesions and, as such, endothelial dysfunction has been shown to predict future
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cardiovascular events [12,13]. In theory, endothelial function can be investigated in any artery of the
body since the atherosclerotic process appears to be universal [14]. The most commonly used method
in clinical research is the flow mediated dilation of the brachial artery (FMD) [15,16]. In HIV-infected
patients, it has repeatedly been found that the FMD is compromised, indicating a higher risk of
cardiovascular disease than in the uninfected population [17,18]. More recently, the endoPAT has
been developed which measures the reactive hyperemic response to transient arterial occlusion of
the digital blood flow. This method is easier to perform and has the contralateral arm as internal
control [19]. A decreased reactive hyperemic index (RHI) has been shown to predict cardiovascular
events in different populations with no apparent heart disease [20,21], but to our knowledge has
never been assessed in HIV-infected patients with full viral suppression. We therefore conducted
a study of HIV-infected patients comparing the RHI with the vasodilator function of the coronary
circulation as previously assessed by 82-rubidium PET/CT. This method enables the quantification of
the absolute myocardial perfusion by injection of a perfusion positron-emitting tracer which allows
for the estimation of the vasodilator function of the coronary circulation. Coronary microvascular
dysfunction reflects the initiation and early changes in the progression toward CAD [22,23]. Indeed,
82-rubidium PET/CT has been found highly predictive of future cardiac events in patients with
suspected CAD [24,25] and patients with diabetes or chronic renal disease with no CAD [26,27] and is
considered the gold standard for assessment of coronary microvascular function [28].
2. Materials and Methods
2.1. Study Population
The participants were recruited from two previous studies described elsewhere [29,30]. In brief,
the first study was a cross-sectional study comparing HIV-infected patients with HIV-uninfected
controls with 82-rubidium PET/CT [29], and the second study was a prospective cohort study of
HIV-infected women in which 44 had undergone 82-rubidium PET/CT [30]. Patients were asked to
participate in the endoPAT study either by e-mail or included at routine visit at the out-patient HIV
clinic. Exclusion criteria were asthma, pregnancy, or alcohol or drug abuse hampering the ability to
adhere to the protocol. All participants were ≥18 years of age and were receiving ART.
2.2. Ethics
All participants received oral and written information and gave written consent before inclusion.
The study was approved by the scientific ethics committee of the capital region of Denmark
[H-C-2008-060, 28 July 2015].
2.3. Data Collection
2.3.1. EndoPAT
All participants were caffeine and nicotine abstinent for 6 h prior to the examination. The EndoPAT
(Itamar Medical, Caesarea, Israel) was performed according to the manufacturer’s instruction in a
single session with a total duration of approximately 30 min including 10 min of rest, 5 min of total
occlusion of the brachial arteries, and 10 min post-occlusion rest. Blood pressures were measured prior
to the test. The ratio between rest and post-occlusion was calculated automatically by the EndoPAT
software, providing the reactive hyperemia index (RHI). All measurements were performed by a single
observer. The mean duration between the 82-rubidium PET/CT and endoPAT studies was 3.3 years
(range 2.0–4.3).
2.3.2. PET Imaging
All patients in this study had previously undergone 82-rubidium PET/CT for study purposes
and the methods have been described in detail elsewhere [29]. In brief, patients were scanned in
Diagnostics 2017, 7, 31 3 of 8
a single session on a Siemens Biograph mCT/PET 128-slice scanner (Siemens Helthcare, Knoxville, TN,
USA) during rest and stress after injection of 82-rubidium supplied from a CardioGen-82 Sr-82/Rb-82
generator (Bracco Diagnostics Inc., Princeton, NJ, USA). Stress images were acquired during the
infusion of adenosine. The myocardial perfusion reserve was calculated as the myocardial stress
perfusion/myocardial rest perfusion. These values were corrected for baseline cardiac work [31].
A low-dose CT was performed for attenuation correction. Coronary artery calcium score (CACS)
images were acquired from a non-contrast breath-hold CT. The CACS was calculated according to the
Agatston score using a threshold of 130 Hounsfield units (HU) [32].
2.3.3. Blood Markers
Blood samples were drawn at routine visits at the HIV out-patient clinic and analysed for CD 4 cell
counts by flow cytometry using the BD Multitest™ (BD Biosciences, San Jose, CA, USA), and HIV RNA
using the AmpliPrep/COBAS, TaqMan HIV-1 test vers. 2.0 (Roche, Branchburg, NJ, USA). Quantitative
determination of blood lipids was performed using the Cholesterol gen2 (Roche Diagnostics, GmBh).
All blood tests were routinely performed by the hospital laboratory.
2.3.4. Risk Score
The Framingham risk score (FRS) was calculated according the published definitions [33] as the
risk of CHD in 10 years.
2.4. Statistical Analyses
Data are shown as mean ± standard error of the mean (SEM), median (IQR) or number
(percentage) where relevant. Correlation analyses were performed by Pearson correlation on
log-transformed data, whereas groups were compared by unpaired t-test on log-transformed data or
by analysis of variance (ANOVA) if more than two groups. Categorical variables were compared by
Chi-square test.
Statistics were performed on SPSS 22 (IBM SPSS statistics for Windows, version 22.0; IBM Corp,
Armonk, NY, USA).
3. Results
Baseline characteristics of the 48 patients are presented in Table 1. Our study included more men
than women with a relatively wide age span of 37–72 years. Two of the patients had diabetes mellitus
type 2, and one of these received antidiabetic medication. One of the patients had hepatitis B (defined
as HBS antigen positive), whereas none had hepatitis C. The mean Framingham risk score (FRS) of
developing coronary heart disease within 10 years was intermediate (10–20%) for the entire group,
but the span was wide (range 0.2–42%), and 63% of the patients had a low FRS. A duration of 3.3 years
was found between the quantification of the MFR and the RHI, and in that time the mean FRS rose
3.4%, which mainly can be attributed to the effect of age in the FRS algorithm.
Table 2 shows that all patients included in this study were receiving ART and they all had high
CD 4 cell counts and no detectable viremia (HIV-RNA < 20 copies/mL). Table 3 shows data from the
82-rubidium myocardial perfusion study and the endoPAT study. In our study, 70% of the patients had
a normal myocardial flow reserve as assessed by 82-rubidium PET/CT and 67% had a normal reactive
hyperemia index.
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Table 1. Baseline characteristics of the patients. 
Parameters N = 48 (%)
Sex  
Male 30 (63) 
Female 18 (37) 
Age, years 55 ± 1 
Interscan duration (years) # 3.3 ± 0.1 
Smoking  
Active 9 (19) 
Former 21 (44) 
Never 18 (37) 
Medication  
Antihypertensive 13 (27) 
Statin 9 (19) 
Anticoagulant 8 (17) 
Perfusion defects on PET/CT 3 (6) 
FRS (CHD 10 years, %)  11.2 ± 1.5  
ΔFRS (CHD 10 years, ) ¤ 3.4 ± 0.9 
Lipids  
Total cholesterol, mmol/L 5.6 ± 0.2 
HDL, mmol/L 1.4 ± 0.1 
LDL, mmol/L 3.4 ± 0.1 
Triglycerids, mmol/L 1.9 ± 0.3 
Systolic Blood Pressure, mmHg 132 ± 3 
Diastolic Blood Pressure, mmHg 78 ± 2 
BMI 24.8 ± 0.7 
Diabetes mellitus 3 (6) 
Blood glucose, mmol/L 6.0 ± 0.3 
Data in this table are presented as number (%) or mean ± standard error of the mean. # Duration in 
years between 82-rubidium PET/CT and endoPAT study. ¤ The mean increase in FRS between the 82-
rubidium PET/C and the endoPAT study. BMI, body mass index (kg/height in m2); CHD, coronary 
heart disease; FRS, Framingham risk score; HDL, high density lipoprotein; LDL, low density 
lipoprotein. 
Table 2. HIV related data. 
Parameters N = 48
CD 4 cell count (106/L), median (IQR) 672 (528–844) 
HIV RNA (copies/mL), median (IQR) 19 (19–19) 
HIV duration, years, median (IQR) 18.0 (12–24) 
ART duration, years, median (IQR) 16 (11–19) 
ART regimens   
2 NRTI + 1 NNRTI  25 (52) 
2 NRTI + PI  8 (17) 
2 NRTI + PI + IH 5 (10) 
Other 10 (21) 
Data in this table are presented as median (IQR, interquartile range) or number (%). ART, 
antiretroviral therapy; IH, integrase inhibitors; NNRTI, non-nucleoside reverse transcriptase 
inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; PI, protease inhibitors. 
Table 3. Data from the original 82-rubidium study and the RHI from the present endoPAT® study. 
Parameters Value
Myocardial flow reserve, mean ± SEM 2.4 ± 1.1 
Myocardial flow reserve tertiles  
<1.5 11% 
≥1.5 < 2.0 19% 
≥2.0 70% 
CACS, median (range) 0 (0–1884) 
RHI, median (range) 1.9 (1.0–4.4) 
Low RHI (<1.67) 33% 
Normal RHI (≥1.67) 67% 
CACS, coronay calcium score; RHI, reactive hyperemia index. 
3.4 ± 0.9
Lipids
Total cholesterol, mmol 5.6 ± 0.2
HDL, m ol/L 1.4 ± 0.1
LD , m ol/L 3.4 ± 0.1
Triglycerids, m ol/ 1.9 ± 0.3
Systolic Blood Pres ure, 132 ± 3
Diastolic Blood Pres ure, 78 ± 2
BMI 24.8 ± 0.7
Diabetes mellitus 3 (6)
Blood glucose, mmol/ 6.0 ± 0.3
Data in this table are presented as number (%) or mean ± standard error of the mean. # Duration in years between
82-rubidium PET/CT and endoPA study.
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Table 2. HIV related data.
Para eters N = 48
CD 4 cell count (106/L), median (IQR) 672 (528–844)
HIV RNA (copies/mL), median (IQR) 19 (19–19)
HIV duration, years, median (IQR) 18.0 (12–24)
ART duration, years, median (IQR) 16 (11–19)
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2 TI + 1 NRTI 25 (52)
2 I + PI 8 (17)
2 I + PI + IH 5 (10)
t r 10 (21)
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IH, integrase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; NRTI, nucleoside reverse
transcriptase inhibitors; PI, protease inhibitors.
Table 3. Data from the original 82-rubidium study and the RHI from the present endoPAT® study.
Parameters Value
Myocardial flow res rve, mean ± SEM 2.4 ± 1.1
Myocardial flow reserve tertiles
<1.5 11%
≥1.5 < 2.0 19%
≥2.0 70%
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As can be seen in Figure 1a, the patients with normal MFR and normal RHI were not the same
since a significant difference was found between the groups in the ANOVA (p = 0.007). Further,
a negative linear correlation was found between the levels of MFR and RHI as shown in Figure 1b
(r = −0.38, p = 0.009), and this linear correlation was not explained by differences in underlying
CHD risk since adjustment for FRS only attenuated this correlation slightly (r = −0.32, p = 0.03).
The patients with a positive CACS (defined as CACS ≥ 1) did not have impaired RHI (2.3 vs. 2.1;
p = 0.55), and a positive correlation was found between CACS and RHI even when adjusting for FRS
(p = 0.72, p = 0.02), whereas an inverse correlation was found for CACS and MFR also adjusting for
FRS (p = −0.70, p = 0.01).
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4. Discussion
In this follow-up study of 48 HIV-infected patients, who had all previously undergone 82-rubidium
PET/CT for study purposes, we studied the correlation between the peripheral flow mediated dilation
(by the so-called reactive hyperemia index using the endoPAT) and the myocardial flow reserve to
assess the value of the endoPAT as a screening tool for early CAD. This method would offer an easy
and non-inva ive ay to assess chang s in coronary vasomotor function a a sign of arly CAD.
Contrary to our hypothesis, we found an inverse correlation betwee the MFR and RHI and as such
we recommend that the endoPAT be validated in larger prospective studies before the implementation
as a screening tool for CAD among HIV-infected patients. Endothelial dysfunction has been shown
to be an early step towards CVD [34,35] and studies have shown a prognostic value of the RHI [21]
as well as a iscrimi ative power for coronary endothelial dysfu ction as assessed by infusion of
acetylcholine dur ng cardiac catheteriz tion [20]. The lack of accordance between the two assessments
in this study can be explained by differences in the underlying vascular physiology. Both methods relay
on endothelial derived responses, but adenosine (used in our study) and dipyridamole (another widely
used vasodilating agent) act on the A2 adenosine receptor (and dipyridamole by inhibition of reuptake
of endogenous adenosine) activating G-proteins, causing relaxation of the coronary circulation. On the
other ha , flow mediated dilation such as the end PAT method is mediated through effects of nitric
oxide (NO) [36]. It therefore follows t at studies using NO-mediate vasodilation of the coronary
arteries are more likely to find a correlation between myocardial flow and reactive hyperemia response,
such as studies using acetylcholine [20,37], whereas studies using the NO-independent adenosine or
dipyridamole tend to report no correlation [38–40].
Interestingly, alrea y one of the first studies to validate the endoPAT against myocardial perfusion
found th t the was no correlation using adenosine [20]. Studies of r active hyperemia in HIV-infected
patients usually use the brachial artery reactivity test and have more or less all shown a tendency
towards impaired endothelial function [17,18]. However, studies comparing flow mediated dilation of
the brachial artery and the circulation in the fingertip have shown that these methods provide different
information [41,42] although a recent meta-analysis showed that they both have predictive value for
cardiovascular events in the non-HIV-infected, general population [43] Further questioning the use
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of the endoPAT as a screening tool in this population was the finding of a normal RHI in patients
with abnormal CACS and an positive correlation between the CACS and RHI. To our knowledge,
this study is the first to compare the coronary and peripheral circulation in HIV-infected patients and
our findings compare well with other studies in the general population using adenosine as myocardial
stress agent, where no correlation between myocardial perfusion and peripheral hyperemia response
is found in patients without signs of CAD. Our results must be interpreted in light of the small sample
of patients and the fact that a high proportion had low FRS and no known CAD. The assessment of the
endoPAT should therefore also be carried out in at larger cohort with higher risk of cardiovascular
disease. Also, an interval of more than three years was found between the 82-rubidium PET/CT
and the endoPAT-study and subjects in the study could have made lifestyle changes which are not
accounted for here, which could possibly affect the reactive hyperemia index. However, we found a
mean increase in FRS of 3.4% between the two studies, which can be explained predominantly by the
increase in age. Finally, this study is cross-sectional including only HIV-infected patients without the
possibility of comparison to a non-infected population.
5. Conclusions
In this first comparative study of the peripheral reactive hyperemia index by the endoPAT and
the myocardial perfusion reserve as assessed by 82-rubidium PET/CT, we found an inverse correlation
between the two methods. Larger prospective studies are warranted to confirm our findings before
any recommendations can be made on the use of the endoPAT as an office-based screening tool for
detection of early CAD among HIV-infected patients.
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